Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility

  • Vet Comp Oncol. 2026 Jun;24(2):370-381. doi: 10.1111/vco.70061.
Huixin Li  1  2 ,  Qiqi Lu  1  2 ,  Xin Huang  1  2 ,  Mengyan Li  1  2 ,  Yiting Zhou  1  2 ,  Mengjuan Chen  1  2 ,  Mengke Qin  1  2 ,  Jingjing Kang  3 ,  Shanshan Xie  1  2 ,  Qingda Meng  1  2
Affiliations
  • 1. College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
  • 2. Research Center for Organoids, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
  • 3. College of Veterinary Medicine, Henan University of Animal Husbandry and Economy, Zhengzhou, China.
PMID: 41847725 DOI: 10.1111/vco.70061
Abstract

Lymphoma constitutes 24% of canine neoplastic diseases and 85% of haematopoietic tumours, with B-cell subtypes accounting for 60%-80% of cases. As the most prevalent spontaneous tumour in canines, this disease model holds significant translational value for human non-Hodgkin lymphoma research. To address diagnostic limitations in canine B-cell lymphoma, we developed a canine-specific CD19 monoclonal antibody (HAC19.1) with high affinity and established a dual-platform detection system compatible with flow cytometry and immunohistochemistry. Additionally, a novel CD19-targeting chimeric antigen receptor (CAR) gene sequence (HUA-1) was engineered and successfully transduced into Jurkat cells via lentiviral vectors, confirming stable CAR membrane expression. This breakthrough provides critical technical groundwork for advancing autologous CAR-T cell therapy in canines.

Keywords
B‐cell lymphoma; CAR‐T; canine; monoclonal antibody.
Products